Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans
- 29 December 2009
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 24 (3), 445-450
- https://doi.org/10.1002/ptr.3074
Abstract
A sensitive LC‐ESI‐MS method with a solid‐phase extraction was established for the determination of bilobalide, ginkgolide A and ginkgolide B in human plasma; bioavailability and pharmacokinetics of three different Ginkgo biloba L. preparations have been investigated. The preparations used in the present single‐dose pharmacokinetic study were different formulations of Ginkgo biloba L. extracts (Geriaforce™ tincture, new Ginkgo fresh plant extract tablets and EGb 761™) with various excipients. The analysis of Ginkgo terpene lactones was performed by LC‐MS on a Zorbax® SB‐C18 column. The mobile phase consisted of water + 0.1% acetic acid and methanol 68/32 (v/v) to 49/51 (v/v) at a flow rate of 200 μL/min. Bilobalide, ginkgolide A and ginkgolide B were monitored using the selected‐ion monitoring (SIM) mode at m/z of 325, 453 and 423, respectively. The amounts of the active compounds (terpene lactones) in the administered products were in the low‐mg range per dose. The assay method was successfully applied to the study of the pharmacokinetics and bioavailability of bilobalide, gingkolide A and ginkgolide B in humans. The resulting maximum concentrations (median) of bilobalide, ginkgolide A and ginkgolide B in plasma after administration of the maximum daily dose of the different Ginkgo products were 3.53, 3.62, and 1.38 ng/mL respectively after administration of Geriaforce™ tincture; 11.68, 7.36, and 4.18 ng/mL, respectively after taking Ginkgo fresh plant extract tablets; and 26.85, 16.44, 9.99 ng/mL, respectively after administration of EGb 761™ tablets. These data are relevant to demonstrate relative bioavailabilities of different Ginkgo biloba L. preparations (Geriaforce™ tincture, new Ginkgo fresh plant extract tablets and EGb 761™). Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 8 references indexed in Scilit:
- Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC–MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in ratsJournal of Chromatography B, 2008
- Simultaneous determination of ginkgo flavonoids and terpenoids in plasma: Ammonium formate in LC mobile phase enhancing electrospray ionization efficiency and capacityJournal of the American Society for Mass Spectrometry, 2008
- Pharmacokinetics of Ginkgo biloba ExtractsPharmacopsychiatry, 2003
- Approaching the problem of bioequivalence of herbal medicinal productsPhytotherapy Research, 2002
- Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparationsJournal of Pharmacy and Pharmacology, 2002
- Pharmacokinetics and Bioavailability of Herbal Medicinal ProductsPhytomedicine, 2002
- Pharmacokinetics and Bioavailability of Quercetin Glycosides in HumansThe Journal of Clinical Pharmacology, 2001
- The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF)Journal of Ethnopharmacology, 1996